PMID- 25962401
OWN - NLM
STAT- MEDLINE
DCOM- 20160630
LR  - 20220330
IS  - 1463-1326 (Electronic)
IS  - 1462-8902 (Print)
IS  - 1462-8902 (Linking)
VI  - 17
IP  - 10
DP  - 2015 Oct
TI  - Progression to insulin therapy among patients with type 2 diabetes treated with 
      sitagliptin or sulphonylurea plus metformin dual therapy.
PG  - 956-64
LID - 10.1111/dom.12489 [doi]
AB  - AIM: To assess time to insulin initiation among patients with type 2 diabetes 
      mellitus (T2DM) treated with sitagliptin versus sulphonylurea as add-on to 
      metformin. METHODS: This retrospective cohort study used GE Centricity electronic 
      medical records and included patients aged >/=18 years with continuous medical 
      records and an initial prescription of sitagliptin or sulphonylurea (index date) 
      with metformin for >/=90 days during 2006-2013. Sitagliptin and sulphonylurea users 
      were matched 1 : 1 using propensity score matching, and differences in insulin 
      initiation were assessed using Kaplan-Meier curves and Cox regression. We used 
      conditional logistic regression to examine the likelihood of insulin use 
      1-6 years after the index date for each year. RESULTS: Propensity score matching 
      produced 3864 matched pairs. Kaplan-Meier analysis showed that sitagliptin users 
      had a lower risk of insulin initiation compared with sulphonylurea users 
      (p = 0.003), with 26.6% of sitagliptin users initiating insulin versus 34.1% of 
      sulphonylurea users over 6 years. This finding remained significant after 
      adjusting for baseline characteristics (hazard ratio 0.76, 95% confidence 
      interval 0.65-0.90). Conditional logistic regression analyses confirmed that 
      sitagliptin users were less likely to initiate insulin compared with 
      sulphonylurea users [odds ratios for years 1-6: 0.77, 0.79, 0.81, 0.57, 0.29 and 
      0.75, respectively (p < 0.05 for years 4 and 5)]. CONCLUSIONS: In this real-world 
      matched cohort study, patients with T2DM treated with sitagliptin had a 
      significantly lower risk of insulin initiation compared with patients treated 
      with sulphonylurea, both as add-on to metformin.
CI  - (c) 2015 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & 
      Sons Ltd.
FAU - Inzucchi, S E
AU  - Inzucchi SE
AD  - Section of Endocrinology, Yale University School of Medicine, New Haven, CT, USA.
FAU - Tunceli, K
AU  - Tunceli K
AD  - Merck & Co., Inc., Kenilworth, NJ, USA.
FAU - Qiu, Y
AU  - Qiu Y
AD  - Merck & Co., Inc., Kenilworth, NJ, USA.
FAU - Rajpathak, S
AU  - Rajpathak S
AD  - Merck & Co., Inc., Kenilworth, NJ, USA.
FAU - Brodovicz, K G
AU  - Brodovicz KG
AD  - Merck & Co., Inc., Kenilworth, NJ, USA.
FAU - Engel, S S
AU  - Engel SS
AD  - Merck & Co., Inc., Kenilworth, NJ, USA.
FAU - Mavros, P
AU  - Mavros P
AD  - Merck & Co., Inc., Kenilworth, NJ, USA.
FAU - Radican, L
AU  - Radican L
AD  - Merck & Co., Inc., Kenilworth, NJ, USA.
FAU - Brudi, P
AU  - Brudi P
AD  - Merck & Co., Inc., Kenilworth, NJ, USA.
FAU - Li, Z
AU  - Li Z
AD  - Asclepius Analytics LLC, New York, NY, USA.
FAU - Fan, C P S
AU  - Fan CP
AD  - Asclepius Analytics LLC, New York, NY, USA.
FAU - Hanna, B
AU  - Hanna B
AD  - Asclepius Analytics LLC, New York, NY, USA.
FAU - Tang, J
AU  - Tang J
AD  - Asclepius Analytics LLC, New York, NY, USA.
FAU - Blonde, L
AU  - Blonde L
AD  - Ochsner Medical Center, New Orleans, LA, USA.
LA  - eng
PT  - Journal Article
DEP - 20150622
PL  - England
TA  - Diabetes Obes Metab
JT  - Diabetes, obesity & metabolism
JID - 100883645
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 0 (Sulfonylurea Compounds)
RN  - 9100L32L2N (Metformin)
RN  - TS63EW8X6F (Sitagliptin Phosphate)
SB  - IM
MH  - Aged
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Drug Administration Schedule
MH  - Drug Prescriptions/*statistics & numerical data
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Hypoglycemic Agents/*administration & dosage
MH  - Insulin/*administration & dosage
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Metformin/*administration & dosage
MH  - Middle Aged
MH  - Propensity Score
MH  - Retrospective Studies
MH  - Sitagliptin Phosphate/*administration & dosage
MH  - Sulfonylurea Compounds/*administration & dosage
MH  - Time Factors
PMC - PMC5033027
OTO - NOTNLM
OT  - DPP-IV inhibitor
OT  - database research
OT  - insulin therapy
OT  - sulphonylureas
OT  - type 2 diabetes
EDAT- 2015/05/13 06:00
MHDA- 2016/07/01 06:00
PMCR- 2016/09/22
CRDT- 2015/05/13 06:00
PHST- 2015/03/23 00:00 [received]
PHST- 2015/05/04 00:00 [revised]
PHST- 2015/05/07 00:00 [accepted]
PHST- 2015/05/13 06:00 [entrez]
PHST- 2015/05/13 06:00 [pubmed]
PHST- 2016/07/01 06:00 [medline]
PHST- 2016/09/22 00:00 [pmc-release]
AID - DOM12489 [pii]
AID - 10.1111/dom.12489 [doi]
PST - ppublish
SO  - Diabetes Obes Metab. 2015 Oct;17(10):956-64. doi: 10.1111/dom.12489. Epub 2015 
      Jun 22.